US · BMEA
Biomea Fusion, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Redwood City, CA 94063
- Website
- biomeafusion.com
Price · as of 2024-12-31
$1.37
Market cap 81.51M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $6.56 | ||||
| 2022 | $13.00 | ||||
| 2023 | $15.36 | ||||
| 2024 | $2.71 |
AI valuation
Our deep-learning model estimates Biomea Fusion, Inc.'s (BMEA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $1.37
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BMEA | Biomea Fusion, Inc. | $1.37 | 81.51M | — | — | — | — | -0.71 | 1.90 | — | -0.34 | -6.23 | 1.90 | 0.00% | — | — | -125.38% | -6089.18% | -98.92% | 0.17 | — | 3.15 | 2.69 | 0.35 | 1134.00% | — | 2030.00% | -122.90% | -5.53 | -5082.67% | 0.00% | 0.00% | 0.00% | -0.34 | -0.40 | — | -9.96 |
| ADVM | Adverum Biotechnologies, … | $4.36 | 96.26M | +263% | -58% | — | +9,149% | -0.69 | 1.28 | 90.60 | -0.44 | -0.30 | 1.28 | -265.30% | -15315.90% | -13092.70% | -169.83% | -313.49% | -74.21% | 1.30 | — | 5.73 | 5.49 | -0.24 | 22772.00% | -7222.00% | 124.00% | -102.48% | -4.04 | -190.05% | 0.00% | 0.00% | 0.00% | -0.37 | -0.61 | 56.62 | -9.89 |
| ALXO | ALX Oncology Holdings Inc… | $2.11 | 114.42M | — | — | — | — | -0.41 | 0.49 | — | 0.42 | — | 0.49 | 0.00% | — | — | -88.91% | -1054.84% | -69.10% | 0.15 | -82.40 | 7.26 | 6.95 | 0.00 | -3102.00% | — | -705.00% | -221.24% | -6.59 | -905.96% | 0.00% | 0.00% | 0.00% | 0.39 | 0.45 | — | -7.15 |
| CAMP | CAMP4 Therapeutics Corpor… | $4.49 | 95.37M | — | -59% | — | — | -1.58 | 1.29 | 125.35 | -0.51 | -0.81 | 1.29 | 100.00% | -8142.33% | -7943.40% | 719.97% | 75.53% | -57.27% | 0.14 | — | 6.92 | 6.68 | 1.08 | 19556.00% | — | 807.00% | -56.29% | -4.75 | 65.45% | 0.00% | 0.00% | 0.00% | -0.50 | -0.57 | 40.39 | -1.91 |
| CBUS | Cibus, Inc. | $3.69 | 194.57M | +439% | -76% | — | — | -0.18 | 0.56 | 12.04 | -0.30 | — | -0.26 | 100.00% | -6062.79% | -5898.36% | -146.63% | -129.39% | -63.21% | 0.39 | -7.56 | 0.85 | 0.78 | -0.09 | -5827.00% | 13456.00% | 1647.00% | -114.67% | -2.92 | -29.47% | 0.00% | 0.00% | 0.00% | -0.28 | -1.24 | 17.17 | -5.24 |
| GUTS | Fractyl Health, Inc. Comm… | $0.47 | 33.88M | +4,277% | +19% | — | +4,370% | -0.89 | 2.16 | 660.15 | -0.61 | — | 2.16 | 46.24% | -100570.97% | -73864.52% | 46.32% | -484.68% | -74.55% | 2.20 | — | 3.63 | 3.41 | 0.05 | -1818.00% | -2250.00% | 5582.00% | -109.60% | -3.31 | -348.68% | 0.00% | 0.00% | 562.21% | -0.60 | -0.84 | 606.77 | -7.20 |
| IMUX | Immunic, Inc. | $1.02 | 100.66M | — | — | — | — | -16.98 | -247.31 | — | -16.85 | — | -247.31 | 0.00% | — | — | -1653.15% | 539.27% | -299.36% | -0.02 | — | 0.75 | 0.64 | 0.16 | -3800.00% | — | 110.00% | -5.21% | -2.80 | 449.10% | 0.00% | 0.00% | 0.00% | -15.84 | -19.02 | — | -17.75 |
| PMVP | PMV Pharmaceuticals, Inc. | $1.70 | 90.46M | — | — | — | — | -1.08 | 0.36 | — | 1.42 | — | 0.36 | 0.00% | — | — | -29.23% | -306.66% | -26.48% | 0.01 | — | 12.22 | 11.79 | 0.54 | -2096.00% | — | -827.00% | -81.87% | -3.57 | -237.51% | 0.00% | 0.00% | 24.06% | 1.23 | 2.02 | — | -0.66 |
| RPTX | Repare Therapeutics Inc. | $2.65 | 114.24M | +786% | -68% | — | — | -0.59 | 0.33 | 0.94 | 1.12 | — | 0.33 | 74.98% | -174.88% | -158.37% | -46.63% | 2379.11% | -39.35% | 0.01 | — | 6.77 | 6.53 | 0.92 | -1031.00% | 458.00% | -4078.00% | -152.11% | -3.02 | 1944.67% | 0.00% | 0.00% | 0.00% | 1.08 | 1.32 | -1.88 | -2.58 |
| STRO | Sutro Biopharma, Inc. | $20.47 | 174.27M | -71% | -71% | — | +6,969% | -0.51 | 2.58 | 1.86 | 0.99 | -0.76 | 2.58 | 88.37% | -384.34% | -366.62% | -234.19% | 108.03% | -53.02% | 0.52 | -7.67 | 2.60 | 2.47 | 0.93 | 6629.00% | -5964.00% | 6789.00% | -168.89% | -1.45 | 88.18% | 0.00% | 0.00% | 114.12% | 0.75 | 0.92 | -2.88 | -3.86 |
| UNCY | Unicycive Therapeutics, I… | $6.93 | 148.94M | +172% | — | — | — | -1.03 | 5.08 | — | -0.34 | -0.30 | 5.08 | 0.00% | — | — | -2028.11% | 209.66% | -160.18% | 0.10 | -452.35 | 1.28 | 1.08 | 0.70 | 33750.00% | -10000.00% | 5658.00% | -75.83% | -1.18 | 187.01% | 2.90% | -3.00% | 46.52% | -0.39 | -0.43 | — | -6.63 |
About Biomea Fusion, Inc.
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
- CEO
- Michael J. Hitchcock
- Employees
- 79
- Beta
- -0.18
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $1.37) − 1 = — (DCF, example).